Allogene Therapeutics (NASDAQ:ALLO) Raised to “Buy” at ValuEngine

Allogene Therapeutics (NASDAQ:ALLO) was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating in a research note issued on Thursday, ValuEngine reports.

Several other brokerages have also commented on ALLO. Canaccord Genuity assumed coverage on shares of Allogene Therapeutics in a research report on Monday. They set a “buy” rating and a $36.00 target price on the stock. JPMorgan Chase & Co. restated a “hold” rating and set a $29.00 target price on shares of Allogene Therapeutics in a research report on Wednesday. William Blair reaffirmed a “buy” rating on shares of Allogene Therapeutics in a research note on Tuesday. Zacks Investment Research downgraded Allogene Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, August 12th. Finally, BTIG Research initiated coverage on Allogene Therapeutics in a research note on Friday, August 9th. They set a “buy” rating and a $37.00 price target for the company. Five investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $36.11.

NASDAQ:ALLO opened at $25.89 on Thursday. The firm’s fifty day moving average price is $28.09 and its 200 day moving average price is $28.06. Allogene Therapeutics has a 1-year low of $23.37 and a 1-year high of $35.55. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.46 and a quick ratio of 13.46. The firm has a market cap of $3.52 billion and a price-to-earnings ratio of -3.93.

Allogene Therapeutics (NASDAQ:ALLO) last issued its earnings results on Tuesday, November 5th. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.04. As a group, analysts expect that Allogene Therapeutics will post -1.94 earnings per share for the current fiscal year.

In related news, insider Alison Moore sold 48,827 shares of the business’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $32.11, for a total value of $1,567,834.97. Insiders own 36.50% of the company’s stock.

A number of hedge funds have recently made changes to their positions in ALLO. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Allogene Therapeutics in the 2nd quarter valued at about $65,000. Tower Research Capital LLC TRC raised its stake in Allogene Therapeutics by 3,789.2% in the 3rd quarter. Tower Research Capital LLC TRC now owns 2,878 shares of the company’s stock valued at $78,000 after purchasing an additional 2,804 shares during the last quarter. Bank of Montreal Can acquired a new position in Allogene Therapeutics in the 2nd quarter valued at about $87,000. BNP Paribas Arbitrage SA acquired a new position in Allogene Therapeutics in the 2nd quarter valued at about $92,000. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. acquired a new position in Allogene Therapeutics in the 2nd quarter valued at about $112,000. 54.48% of the stock is owned by hedge funds and other institutional investors.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma.

Recommended Story: What are Closed-End Mutual Funds?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Allogene Therapeutics (NASDAQ:ALLO)

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.